Fresenius Archives - Page 2 of 2 - Medical Design Sourcing

Women researchers receive a fraction of funding from the world’s biggest medtech companies

The gender divide in medtech extends beyond leadership and into funding for investigational studies by U.S. physicians.

Only 6.7% of physicians who received research payments from the world’s largest medical device companies in 2020 were women, according to an analysis of Medical Design & Outsourcing’s Big 100 list of medtech companies and CMS Open Payments data.

Among the 20 medical device companies that fund research by U.S. physicians are 3M, Abbott, BD, Boston Scientific, Johnson & Johnson (dba J&J Surgical Vision and J&J Vision Care), Medtronic (dba Medtronic, Medtronic Minimed, Medtronic USA, Medtronic Vascular), Royal Philips (dba Philips Electronics), Stryker and Zimmer Biomet.

Together, those companies paid $3.9 million to 312 doctors in 2020, but only 21 were women, receiving a collective $402,600.

Women physicians, on average, received 15.7% of payments from each of the top medtech companies, but accounted f…

Fresenius Medical Care investing $25M in Humacyte as it goes public in SPAC deal

Fresenius Medical Care announced today that it will invest $25 million in Humacyte in connection with the merger of Humacyte and a SPAC.

Humacyte, which develops implantable human acellular vessels for multiple vascular repair, reconstruction and replacement, entered into a merger with a special purpose acquisition company (SPAC), leading Fresenius to increase its position in the newly combined entity as the lead investor of a private investment in public equity (PIPE), according to a news release.

Fresenius acquired a stake in Humacyte in 2018 for $150 million and agreed on a strategic partnership and now its original stake will be exchanged for shares in the combined company, which will remain under the Humacyte name and will trade on the Nasdaq market under the “HUMA” ticker.

Among several applications, Humacyte develops its implantable vessels to be non-immunogenic and available “off the shelf” for uses such as vascular access…

Fresenius to provide more home dialysis machines to DaVita

A NxStage home hemodialysis machine [Image courtesy of Fresenius Medical Care] Fresenius Medical Care North America (FMCNA) has expanded its agreement with DaVita Kidney Care to provide NxStage home hemodialysis machines and related technology to DaVita’s U.S. patients.

“We are excited to expand our longstanding collaboration with DaVita to help more patients benefit from the portability, dependability, and flexibility of our NxStage home machines, which are designed to be easy to use,” Joe Turk, president of Home and Critical Care Therapies for FMCNA, said in a news release out today.

Under the agreement, DaVita patients will also access Nx2me Connected Health, a connected health platform that simplifies collection and sharing of treatment information with the dialysis clinic and care team. Nx2me Connected Health accesses treatment information directly from home hemodialysis machines.

Keith Hartman, group vice president for DaVita home modalities, sa…